NBIX and VYGR Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases.

Voyager to receive up-front consideration of $175M including a $39M equity investment.

#CNS基因治疗# $神经分泌生物科学(NBIX)$ $Voyager Therapeutics(VYGR)$